[1]AlzheonReports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease. Retrieved September 20, 2022 from网页链接 [2] In one-year update,Alzheongoes bi...
Strong biologic rationale: 3-fold higher levels of toxic Aβ oligomers in brain compared to non-carriers Alzheimer’s clinical onset ~10 years earlier compared to non-carriers Major unmet medical need *Valiltramiprosate Phase 2 biomarker trial includes baseline CSF screening in APOE4/4 and APOE3...
Fully enrolled Phase 2 study in APOE4 carriers is evaluating effects on plasma biomarkers, including hyperphosphorylated tau (p-tau181) and beta amyloid (A尾42 and A尾40). Plasma p-tau181 is elevated in AD and reduced by efficacious doses of lecanemab and aducanumab. APOLLOE4 Phase 3 ...
The AAIC presentation:Effects of Oral ALZ-801, an Amyloid Oligomer Inhibitor, on Plasma Biomarkers in APOE4 Carriers with Early Alzheimer’s Disease: Results of Six-month Interim Analysis from a Phase 2 ...
(eGFR), concomitant acetylcholinesterase inhibitor (AChEI) use, and tablet lot] were evaluated.#The steady-state plasma PK results were closely aligned with the previous 2-week PK in the ALZ-801 phase 1b study in APOE4 carrier subjects with AD, as well as a phase 1 7-day PK study in...
ALZ-801 is a promising candidate DMT for AD, with a phase 3 trial of ALZ-801 ongoing specifically for apolipoprotein E (APOE) ε4 homozygous patients with early-stage AD. This study aimed to examine the effects of ALZ-801 on Aβ assembly and explore its toxicological profile. Thioflavin T...